HANSA BIOPHARMA AB revenue breakdown overview

HANSA BIOPHARMA AB revenue for the last year amounted to 134.10 M SEK, the most of which — 134.09 M SEK — came from its highest performing source at the moment, Antibody-cleaving Enzyme Technology Platform, the year earlier bringing 154.53 M SEK. The greatest contribution to the revenue figure was made by Europe (excluding Sweden) — last year it brought HANSA BIOPHARMA AB 106.67 M SEK, and the year before that — 85.57 M SEK.